Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Genetically Determined Serum Levels of Mannose-Binding Lectin Correlate Negatively with Common Carotid Intima-Media Thickness in Systemic Lupus Erythematosus

LONE N. TROELSEN, PETER GARRED, BURIS CHRISTIANSEN, CHRISTIAN TORP-PEDERSEN and SØREN JACOBSEN
The Journal of Rheumatology September 2010, 37 (9) 1815-1821; DOI: https://doi.org/10.3899/jrheum.100158
LONE N. TROELSEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lone.troelsen@mail.dk
PETER GARRED
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BURIS CHRISTIANSEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTIAN TORP-PEDERSEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SØREN JACOBSEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Patients with systemic lupus erythematosus (SLE) have excess cardiovascular morbidity and mortality due to accelerated atherosclerosis that cannot be attributed to traditional cardiovascular risk factors alone. Variant alleles of the mannose-binding lectin gene (MBL2) causing low serum concentrations of functional mannose-binding lectin (MBL) are associated with SLE and development of atherosclerosis. Recent studies show that these variant alleles are associated with increased risk of arterial thrombosis and cardiovascular disease in patients with SLE. Intima-media thickness of the common carotid artery (ccIMT) is a validated noninvasive anatomic measure of subclinical atherosclerosis. In a cross-sectional study we examined the relation among ccIMT, MBL2 genotypes, and serum concentrations of MBL.

Methods. The MBL2 extended genotypes (YA/YA, YA/XA, XA/XA, YA/YO, XA/YO, YO/YO) and serum concentrations of MBL were determined in 41 outpatients with SLE. ccIMT was measured by means of ultrasonography. Traditional and nontraditional cardiovascular risk modifiers were assessed and controlled for.

Results. Using nonparametric Mann-Whitney tests we found a significant difference in ccIMT between low-expressing (XA/XA+YA/YO+XA/YO+YO/YO) and high-expressing (YA/YA+YA/XA) MBL2 genotypes (p = 0.034). The difference in ccIMT remained significant in multivariable analysis adjusting for traditional and nontraditional cardiovascular risk modifiers (p = 0.049). ccIMT was negatively correlated to serum concentrations of MBL (Spearman rho = −0.33, p = 0.037). This relation also remained significant in multivariable analysis (p = 0.042).

Conclusion. In this group of SLE patients, MBL2 low-expressing genotypes and low serum levels of MBL were correlated with ccIMT, independent of the effects of traditional and nontraditional cardiovascular risk modifiers.

  • SYSTEMIC LUPUS ERYTHEMATOSUS
  • ATHEROSCLEROSIS
  • ULTRASONOGRAPHY
  • RISK FACTORS
  • MANNOSE-BINDING LECTIN

Patients with systemic lupus erythematosus (SLE) have increased incidence of preclinical atherosclerosis1,2,3,4 and cardiovascular disease (CVD) compared to the general population5,6. The increased cardiovascular risk in SLE cannot be fully explained by traditional cardiac risk factors alone7,8. Accumulating evidence indicates that inflammation plays a key role in development of atherosclerosis from plaque initiation to plaque rupture and thrombus formation9,10. SLE is a chronic inflammatory disease with increased levels of proatherogenic mediators11,12,13. Several studies suggest that disease-specific factors other than traditional risk factors may play an additional role in development of atherosclerosis and CVD in SLE8,14. Potent antiinflammatory medication provides survival benefits by reducing development of atherosclerosis and risk of coronary disease in patients with SLE14,15. Thus, it is likely that factors modulating the inflammatory response in SLE may affect development of atherosclerosis and CVD in SLE patients.

Mannose-binding lectin (MBL) is a liver-derived serum protein involved in innate immune defense16. It binds microorganisms and cellular debris through the carbohydrate recognition domain. Serum MBL can directly opsonize pathogens and enhance the activity of phagocytic cells or it can activate complement via the lectin pathway. Differences in MBL serum concentrations can partly be explained by structural variant alleles in the human MBL gene (MBL2) on chromosome 1017. The normal genotype is associated with the highest serum concentrations of MBL. Heterozygosity for MBL2 structural variant alleles causes an average 85%–90% drop in the serum concentration of functional MBL and homozygosity for structural variant alleles are devoid of functional MBL. The normal MBL2 allele is denoted A, and the common designation for the variant alleles is O. In addition to the effect of the structural allelic variants, polymorphisms in the promoter region of MBL2 gene affect serum levels of MBL. In particular, a base substitution at codon −221 (G to C; promoter allele X) is associated with lower serum concentrations of MBL.

Studies indicate an association between MBL deficiency and susceptibility for SLE18, and low MBL concentrations have been related to the clinical course of SLE, e.g., complicating infections19 and renal involvement20. In a followup study we observed that homozygosity for MBL2 variant alleles was associated with an increased risk of arterial thrombosis among patients with SLE21. This is in accord with another study where SLE patients with MBL deficiency had a 3.1 increased risk of CVD22. Studies of various populations have shown that the presence of dysfunctional alleles and low serum levels of MBL are associated with increased risk of atherosclerosis and coronary artery disease23,24,25,26.

Intima-media thickness of the common carotid artery (ccIMT) determined by high-resolution B-mode ultrasonography is a useful noninvasive anatomic measure of subclinical CVD and constitutes an excellent surrogate marker of generalized atherosclerosis and coronary artery disease27. Increased ccIMT has been observed in patients with SLE compared to controls1,4 and correlates with several traditional and nontraditional cardiovascular risk factors in SLE1,4,28,29.

Based on these findings we hypothesized that low-expressing MBL2 genotypes and low serum levels of MBL are associated with increased subclinical atherosclerosis measured by ccIMT in patients with SLE.

MATERIALS AND METHODS

Patients

Forty-one consecutive unrelated white Danish outpatients with SLE attending the Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, were included from August 2005 to July 2006. All patients fulfilled the American College of Rheumatology (ACR) classification criteria for SLE30. At inclusion, all patients were subjected to a detailed interview and underwent a clinical examination. Fasting serum samples were collected and stored at −80°C. Within 24 weeks of recruitment ccIMT was measured in all patients. The study was approved by the local scientific ethical committee (KF 01 261669). Written informed consent was obtained from each patient.

Clinical and laboratory assessment

Traditional cardiovascular risk modifiers included in this study were: sex, age, blood pressure calculated as mean blood pressure (1/3 × systolic blood pressure + 2/3 × diastolic blood pressure), smoking calculated as “pack-years” [mean number of packs (= 20 cigarettes) per day × number of years smoking], body mass index (BMI), total cholesterol, homeostatic model assessment of insulin resistance (HOMA1-IR) [(insulin (mU/l) × glucose (mmol/l))/22.5]31. Nontraditional cardiovascular risk modifiers were disease duration, highly sensitive C-reactive protein (hsCRP), SLE Disease Activity Index (SLEDAI)32, Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI)33, and treatment-ever with glucocorticoids or other immunosuppressants. All patients were interviewed and examined by the same physician. Clinical charts were used to verify information regarding treatment with antiinflammatory drugs.

Genotyping and detection of MBL serum concentration

Detection of MBL2 alleles was as described34. All patients were genotyped for the three MBL2 structural polymorphisms and for the promoter polymorphism in position —221 (X/X, X/Y, Y/Y). The following MBL2 extended genotypes were tested for: YA/YA, YA/XA, XA/XA, YA/YO, XA/YO, and YO/YO. Serum concentrations of MBL were measured in a double ELISA based on a monoclonal anti-MBL antibody35. Low-expressing genotypes were defined to include XA/XA, YA/YO, XA/YO, and YO/YO based on the genotypes expressing the lowest MBL serum concentrations (Figure 1), while YA/YA and YA/XA were defined as high-expressing genotypes due to their associations with the highest MBL serum concentrations.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Serum concentrations of mannose-binding lectin (MBL) in relation to MBL2 extended genotypes in 41 patients with SLE. Data are presented as box plots: boxes represent 25th to 75th percentiles, lines within boxes the median, and the lines outside represent 10th and 90th percentiles.

*Outliers.

ccIMT measurement

Measurement of ccIMT was performed by using an Acuson Cypress ultrasound apparatus with a 7 MHz linear probe. A still picture of the common carotid artery proximal to the bulbus caroticus was produced, ensuring a distinct picture of intima and media on the far wall of the vessel (the intima-media). Thickness was measured 3 times using the electronic calipers of the ultrasound apparatus and the picture was digitally stored for future reference. Measurements were performed on both carotid arteries. A mean for both arteries was calculated and used in analysis. To ensure correct calibration of ccIMT measurements these were also performed in 10 healthy subjects (8 women, 2 men) with a median age of 44 years (range 25–72 yrs).

Statistical analysis

The differences in ccIMT between SLE patients and healthy individuals and between low-expressing and high-expressing MBL2 genotypes were examined by nonparametric Mann-Whitney test. Spearman’s rank correlation analysis was performed to examine the relation between ccIMT and MBL serum concentrations. Multivariable regression analyses were performed to examine the relationship among ccIMT, MBL2 low- and high-expressing genotypes, serum MBL, traditional and nontraditional risk factor variables. Due to the number of study subjects, the number of variables included into the regression model had to be limited, focusing on MBL, demographics, traditional cardiovascular risk factors, disease activity, and medication. To fit the linear regression model regarding linearity, variance homogeneity, and normal distribution, ccIMT was log-transformed. Processing of study data was done using SPSS 15. Statistical significance was defined as p value < 0.05.

RESULTS

Clinical and laboratory variables for all patients at inclusion are shown in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Clinical and laboratory variables assessed in the cohort of 41 patients with systemic lupus erythematosus. Except where indicated otherwise, values are median [quartiles] (range).

The median ccIMT of SLE patients was 0.57 mm (range 0.37 to 0.98 mm), which was significantly thicker (p = 0.029) than in the healthy subjects, where median ccIMT was 0.46 mm (range 0.40 to 0.78 mm).

Median serum concentration of MBL was 0.85 mg/l (range 0 to 4.3 mg/l). Serum MBL varied with the extended MBL2 genotypes (YA/YA, YA/XA, XA/XA, YA/YO, XA/YO, and YO/YO) as shown in Figure 1. Seventeen patients had the low-expressing genotypes (XA/XA, YA/YO, XA/YO, and YO/YO) and 24 patients had the high-expressing genotypes (YA/YA, YA/XA). Variation in ccIMT according to low-expressing and high-expressing MBL2 genotype is shown in Figure 2. Using nonparametric Mann-Whitney test we found a significant difference in ccIMT between the low- and high-expressing MBL2 genotypes (p = 0.034). The difference in ccIMT remained significant in multivariable analysis adjusting for traditional and nontraditional cardiovascular risk modifiers (p = 0.049; Table 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Common carotid intima-media thickness (ccIMT) in relation to MBL2 low-expressing (17 patients) and high-expressing (24 patients) genotypes in 41 patients with SLE. Data are presented as box plots: boxes represent 25th to 75th percentiles, lines within boxes the median, and the lines outside represent 10th and 90th percentiles. Circles indicate outliers.

View this table:
  • View inline
  • View popup
Table 2.

Results of multivariable regression analysis between common carotid intima-media thickness (ccIMT)*, MBL2 low-expressing genotypes, and traditional and nontraditional cardiovascular risk modifiers.

The relationship between ccIMT and serum concentrations of MBL is shown in Figure 3. ccIMT and serum MBL correlated negatively with a Spearman rho = −0.33 (p = 0.037). In a multivariate regression analysis we found that this negative association remained significant after adjustment for traditional and nontraditional cardiovascular risk modifiers (p = 0.042; Table 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Common carotid intima-media thickness (ccIMT) in relation to serum concentrations of mannose-binding lectin (MBL).

View this table:
  • View inline
  • View popup
Table 3.

Results of multivariable regression analysis between common carotid intima-media thickness (ccIMT)*, serum MBL, and traditional and nontraditional cardiovascular risk modifiers.

DISCUSSION

Two studies have related MBL deficiency with CVD in SLE patients21,22. Since patients with SLE have increased incidence of atherosclerosis that cannot be explained solely by excess of traditional cardiovascular risk factors and since MBL deficiency has been associated with atherosclerosis and CVD in other populations23,24,25,26, we wanted to examine if MBL2 variant alleles and low serum MBL concentrations in SLE patients were associated with increased sub-clinical atherosclerosis measured by ultrasonography. Our results showed that ccIMT was increased in SLE patients compared to healthy individuals and that this increase was related to genetically determined low serum levels of MBL independently of the effects of traditional and nontraditional cardiovascular risk modifiers.

ccIMT ≥ 0.60 mm is a marker of generalized atherosclerosis36. In our study, the mean ccIMT was 0.62 mm, in accord with previous findings in SLE patients1,4. Several associations between increased ccIMT and traditional cardiovascular risk factors have been observed in patients with SLE1,4,28,29. In some studies disease duration29, SLEDAI37, and SDI38 have been associated with increased subclinical atherosclerosis in SLE patients, whereas other studies failed to find significant associations among disease duration, SLEDAI, SDI, and atherosclerosis in univariate and/or multivariate analysis28,39. Increase of ccIMT in SLE patients has also been shown to be associated with complement activation29 and proinflammatory high-density lipoprotein28. Moreover, treatment with antiinflammatory drugs (in particular prednisolone) was also associated with development of atherosclerosis in patients with SLE28,39. Due to the relatively low number of patients included in this study only a limited number of variables could be added into the multivariable analysis. Since a higher number of studies find significant associations among traditional cardiovascular risk factors, treatment with antiinflammatory drugs, and atherosclerosis in SLE patients, we chose to focus on these risk factor variables in our analysis. A priori we chose not to include SDI in the analysis since it is partly defined by atherosclerotic events, and therefore per definition could be expected to covary with ccIMT. Except for age, ccIMT was unrelated to other traditional and nontraditional cardiovascular risk factors in univariate (data not shown) and multivariate analyses in our study. It is likely that differences in study design, in risk factor variables, and in medication, age and duration of disease may influence the associations studied. The discrepancies in our results could also be due to uneven distributions of confounders not accounted for, which may include MBL.

MBL can enhance the clearance of pathogens, dying host cells, and cellular debris16, as well as circulating immune complexes40,41,42. Based on these capabilities several pathophysiological mechanisms may be suggested to explain the relation between deficiency of functional MBL and development of atherosclerosis in patients with SLE. A theory of infection in atherosclerosis has not been proven, but several studies have shown that chronic infections including periodontitis and infections with Helicobacter pylori and Chlamydia pneumoniae may be associated with development of atherosclerosis and cardiovascular disease43. As MBL deficiency is associated with increased risk of infections in SLE patients19; as infection with C. pneumoniae leads mainly to development and progression of severe coronary artery disease in patients with variation in the MBL gene44; and as homozygosity for MBL2 variant alleles is associated with greater impairment in flow mediated dilatation during infection in childhood24, it could be hypothesized that deficiency of MBL in SLE patients results in defective clearance of infectious material that aggravates ongoing inflammatory processes leading to development of atherosclerosis.

Endothelial apoptosis contributes to the loss of endothelial integrity and thereby to the initiation of atherosclerosis45. In patients with SLE the number of apoptotic circulating endothelial cells is increased, which correlates with the endothelial dysfunction observed in these patients46. Moreover, SLE patients produce a heterogeneous array of antibodies that bind to the endothelium47,48 and in vitro studies have shown that some of these antibodies induce endothelial apoptosis49. Lack of functional MBL may lead to decreased removal of apoptotic endothelial cells in patients with SLE. As high levels of circulating apoptotic endothelial cells may induce production of autoantibodies directed against endothelial cells, this could lead to dysfunction of the endothelium and enhance development of atherosclerosis in patients with SLE.

In contrast to our observations in SLE patients, the normal MBL2 genotype and high serum levels of MBL have also been shown to increase the risk of CVD in apparently healthy men50, in patients with rheumatoid arthritis (RA)51, and in patients with diabetes52; and high serum levels of MBL and the lectin pathway of complement initiates the inflammatory reaction seen in relation to ischemia reperfusion53,54. A differentiated role of MBL in atherosclerosis development was recently observed in patients with RA55. This paradox is probably a key issue in understanding the role of MBL in human disease. Thus, it is likely that a fine balance in the vessel wall during all stages of development of atherosclerosis determines whether MBL may be advantageous or disadvantageous. Under circumstances allowing the physiological opsonic activity of MBL, which is advantageous, lack of functional MBL may increase inflammation due to dysfunctional sequestration of harmful material from the vessel wall. On the other hand, if high levels of MBL mediate excessive complement activation the process may become detrimental. However, based on our results we are not able to determine causal relations. Experimental studies should be performed to examine the mechanisms by which MBL may influence the various stages of atherosclerosis in SLE patients and in other study populations.

Our results support the notion that genetically determined low levels of MBL are associated with the development of atherosclerotic disease in SLE. As our study population was relatively small, new studies based on larger study populations should be performed to confirm our data and to examine if our findings may be applicable in other disease settings and in healthy individuals.

Footnotes

  • Supported by grants from The Danish Rheumatism Association, The Novo Nordisk Research Foundation, The Capital Region of Denmark, and Rigshospitalet, Copenhagen University Hospital.

  • Accepted for publication April 26, 2010.

REFERENCES

  1. 1.↵
    1. Colombo BM,
    2. Cacciapaglia F,
    3. Puntoni M,
    4. Murdaca G,
    5. Rossi E,
    6. Rodriguez G,
    7. et al.
    Traditional and nontraditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8:309–15.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. El-Magadmi M,
    2. Bodill H,
    3. Ahmad Y,
    4. Durrington PN,
    5. Mackness M,
    6. Walker M,
    7. et al.
    Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399–404.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Lima DS,
    2. Sato EI,
    3. Lima VC,
    4. Miranda F Jr.,
    5. Hatta FH
    . Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002;29:292–7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Lopez LR,
    2. Salazar-Paramo M,
    3. Palafox-Sanchez C,
    4. Hurley BL,
    5. Matsuura E,
    6. Garcia-De La Torre I
    . Oxidized low-density lipoprotein and beta 2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006;15:80–6.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Jonsson H,
    2. Nived O,
    3. Sturfelt G
    . Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine Baltimore 1989;68:141–50.
    OpenUrlPubMed
  6. 6.↵
    1. Manzi S,
    2. Meilahn EN,
    3. Rairie JE,
    4. Conte CG,
    5. Medsger TA Jr.,
    6. Jansen-McWilliams L,
    7. et al.
    Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408–15.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Bessant R,
    2. Hingorani A,
    3. Patel L,
    4. MacGregor A,
    5. Isenberg DA,
    6. Rahman A
    . Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 2004;43:924–9.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Esdaile JM,
    2. Abrahamowicz M,
    3. Grodzicky T,
    4. Li Y,
    5. Panaritis C,
    6. du Berger R,
    7. et al.
    Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331–7.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hansson GK
    . Mechanisms of disease — inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–95.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Libby P
    . Inflammation in atherosclerosis. Nature 2002;420:868–74.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Barnes EV,
    2. Narain S,
    3. Naranjo A,
    4. Shuster J,
    5. Segal MS,
    6. Sobel ES,
    7. et al.
    High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005;14:576–82.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Capper ER,
    2. Maskill JK,
    3. Gordon C,
    4. Blakemore AI
    . Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol 2004;138:348–56.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Svenungsson E,
    2. Fei GZ,
    3. Jensen-Urstad K,
    4. de Faire U,
    5. Hamsten A,
    6. Frostegard J
    . TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003;12:454–61.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Roman MJ,
    2. Shanker BA,
    3. Davis A,
    4. Lockshin MD,
    5. Sammaritano L,
    6. Simantov R,
    7. et al.
    Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399–406.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Petri M,
    2. Lakatta C,
    3. Magder L,
    4. Goldman D
    . Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Dommett RM,
    2. Klein N,
    3. Turner MW
    . Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006;68:193–209.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Garred P,
    2. Larsen F,
    3. Seyfarth J,
    4. Fujita R,
    5. Madsen HO
    . Mannose-binding lectin and its genetic variants. Genes Immun 2006;7:85–94.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Monticielo OA,
    2. Mucenic T,
    3. Xavier RM,
    4. Brenol JC,
    5. Chies JA
    . The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol 2008;27:413–9.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Garred P,
    2. Madsen HO,
    3. Halberg P,
    4. Petersen J,
    5. Kronborg G,
    6. Svejgaard A,
    7. et al.
    Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999;42:2145–52.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Piao W,
    2. Liu CC,
    3. Kao AH,
    4. Manzi S,
    5. Vogt MT,
    6. Ruffing MJ,
    7. et al.
    Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus. J Rheumatol 2007;34:1506–13.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Ohlenschlaeger T,
    2. Garred P,
    3. Madsen HO,
    4. Jacobsen S
    . Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260–7.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Font J,
    2. Ramos-Casals M,
    3. Brito-Zeron P,
    4. Nardi N,
    5. Ibanez A,
    6. Suarez B,
    7. et al.
    Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology 2007;46:76–80.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Best LG,
    2. Davidson M,
    3. North KE,
    4. MacCluer JW,
    5. Zhang Y,
    6. Lee ET,
    7. et al.
    Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians — The Strong Heart Study. Circulation 2004;109:471–5.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Charakida M,
    2. Donald AE,
    3. Leary S,
    4. Halcox JP,
    5. Turner MW,
    6. Johnson M,
    7. et al.
    Endothelial response to childhood infection: The role of mannose-binding lectin (MBL). Atherosclerosis 2010;208:217–21.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Hegele RA,
    2. Ban MR,
    3. Anderson CM,
    4. Spence JD
    . Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Invest Med 2000;48:198–202.
    OpenUrlPubMed
  26. 26.↵
    1. Madsen HO,
    2. Videm V,
    3. Svejgaard A,
    4. Svennevig JL,
    5. Garred P
    . Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet 1998;352:959–60.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Simons PC,
    2. Algra A,
    3. Bots ML,
    4. Grobbee DE,
    5. van der Graaf Y
    . Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999;100:951–7.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. McMahon M,
    2. Grossman J,
    3. Skaggs B,
    4. Fitzgerald J,
    5. Sahakian L,
    6. Ragavendra N,
    7. et al.
    Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428–37.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Rua-Figueroa I,
    2. Arencibia-Mireles O,
    3. Elvira M,
    4. Erausquin C,
    5. Ojeda S,
    6. Francisco F,
    7. et al.
    Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2 year longitudinal study. Ann Rheum Dis 2010 Apr 13. Epub ahead of print
  30. 30.↵
    1. Tan EM,
    2. Cohen AS,
    3. Fries JF,
    4. Masi AT,
    5. McShane DJ,
    6. Rothfield NF,
    7. et al.
    The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Wallace TM,
    2. Levy JC,
    3. Matthews DR
    . Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–95.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Bombardier C,
    2. Gladman DD,
    3. Urowitz MB,
    4. Caron D,
    5. Chang CH
    . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.
    The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Madsen HO,
    2. Garred P,
    3. Thiel S,
    4. Kurtzhals JAL,
    5. Lamm LU,
    6. Ryder LP,
    7. et al.
    Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013–20.
    OpenUrlAbstract
  35. 35.↵
    1. Garred P,
    2. Madsen HO,
    3. Kurtzhals JAL,
    4. Lamm LU,
    5. Thiel S,
    6. Hey AS,
    7. et al.
    Diallelic polymorphism may explain variations of the blood-concentration of mannan-binding protein in eskimos, but not in black-africans. Eur J Immunogenet 1992;19:403–12.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Veller MG,
    2. Fisher CM,
    3. Nicolaides AN,
    4. Renton S,
    5. Geroulakos G,
    6. Stafford NJ,
    7. et al.
    Measurement of the ultrasonic intima-media complex thickness in normal subjects. J Vasc Surg 1993;17:719–25.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Shang Q,
    2. Tam LS,
    3. Li EK,
    4. Yip GW,
    5. Yu CM
    . Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus 2008;17:1096–102.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Ghosh P,
    2. Kumar A,
    3. Kumar S,
    4. Aggarwal A,
    5. Sinha N,
    6. Misra R
    . Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 2009;28:1259–65.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Schanberg LE,
    2. Sandborg C,
    3. Barnhart HX,
    4. Ardoin SP,
    5. Yow E,
    6. Evans GW,
    7. et al.
    Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009;60:1496–507.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Arnold JN,
    2. Wormald MR,
    3. Suter DM,
    4. Radcliffe CM,
    5. Harvey DJ,
    6. Dwek RA,
    7. et al.
    Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem 2005;280:29080–7.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Malhotra R,
    2. Wormald MR,
    3. Rudd PM,
    4. Fischer PB,
    5. Dwek RA,
    6. Sim RB
    . Glycosylation changes of Igg associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1:237–43.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Roos A,
    2. Bouwman LH,
    3. van Gijlswijk-Janssen DJ,
    4. Faber-Krol MC,
    5. Stahl GL,
    6. Daha MR
    . Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167:2861–8.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Palm F,
    2. Urbanek C,
    3. Grau A
    . Infection, its treatment and the risk for stroke. Curr Vasc Pharmacol 2009;7:146–52.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Rugonfalvi-Kiss S,
    2. Endresz V,
    3. Madsen HO,
    4. Burian K,
    5. Duba J,
    6. Prohaszka Z,
    7. et al.
    Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. Circulation 2002;106:1071–6.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Stoneman VE,
    2. Bennett MR
    . Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci Lond 2004;107:343–54.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Rajagopalan S,
    2. Somers EC,
    3. Brook RD,
    4. Kehrer C,
    5. Pfenninger D,
    6. Lewis E,
    7. et al.
    Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103:3677–83.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Dieude M,
    2. Senecal JL,
    3. Raymond Y
    . Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell autoantibody-positive systemic lupus erythematosus patients. Arthritis Rheum 2004;50:3221–31.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Hill MB,
    2. Phipps JL,
    3. Hughes P,
    4. Greaves M
    . Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. Br J Haematol 1998;103:416–21.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Moscato S,
    2. Pratesi F,
    3. Bongiorni F,
    4. Scavuzzo MC,
    5. Chimenti D,
    6. Bombardieri S,
    7. et al.
    Endothelial cell binding by systemic lupus antibodies: functional properties and relationship with anti-DNA activity. J Autoimmun 2002;18:231–8.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Keller TT,
    2. van Leuven SI,
    3. Meuwese MC,
    4. Wareham NJ,
    5. Luben R,
    6. Stroes ES,
    7. et al.
    Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol 2006;26:2345–50.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Troelsen LN,
    2. Garred P,
    3. Madsen HO,
    4. Jacobsen S
    . Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum 2007;56:21–9.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Hansen TK,
    2. Tarnow L,
    3. Thiel S,
    4. Steffensen R,
    5. Stehouwer CD,
    6. Schalkwijk CG,
    7. et al.
    Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004;53:1570–6.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Jordan JE,
    2. Montalto MC,
    3. Stahl GL
    . Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001;104:1413–8.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Walsh MC,
    2. Bourcier T,
    3. Takahashi K,
    4. Shi L,
    5. Busche MN,
    6. Rother RP,
    7. et al.
    Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005;175:541–6.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Troelsen LN,
    2. Garred P,
    3. Christiansen B,
    4. Torp-Pedersen C,
    5. Christensen IJ,
    6. Narvestad E,
    7. et al.
    Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis. Mol Immunol 2010;47:713–18.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 9
1 Sep 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Genetically Determined Serum Levels of Mannose-Binding Lectin Correlate Negatively with Common Carotid Intima-Media Thickness in Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Genetically Determined Serum Levels of Mannose-Binding Lectin Correlate Negatively with Common Carotid Intima-Media Thickness in Systemic Lupus Erythematosus
LONE N. TROELSEN, PETER GARRED, BURIS CHRISTIANSEN, CHRISTIAN TORP-PEDERSEN, SØREN JACOBSEN
The Journal of Rheumatology Sep 2010, 37 (9) 1815-1821; DOI: 10.3899/jrheum.100158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Genetically Determined Serum Levels of Mannose-Binding Lectin Correlate Negatively with Common Carotid Intima-Media Thickness in Systemic Lupus Erythematosus
LONE N. TROELSEN, PETER GARRED, BURIS CHRISTIANSEN, CHRISTIAN TORP-PEDERSEN, SØREN JACOBSEN
The Journal of Rheumatology Sep 2010, 37 (9) 1815-1821; DOI: 10.3899/jrheum.100158
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications
  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire